Impact of gastrointestinal events on patient-reported outcomes in Asia-Pacific women with osteoporosis: baseline results of the MUSIC OS-AP study

A. Modi 1 · P. R. Ebeling 2 · M. S. Lee 3 · Y. K. Min 4 · A. Mithal 5 · X. Yang 1 · S. Baidya 6 · S. Sen 1 · S. Sajjan 1

Received: 13 February 2017 / Accepted: 21 May 2017 / Published online: 17 July 2017 © The Author(s) 2017. This article is an open access publication

Abstract

Summary The purpose of this study was to describe the impact of gastrointestinal events on patient-reported outcomes and health care resource use among Asia-Pacific women with postmenopausal osteoporosis. The results of this study show that gastrointestinal events decreased adherence, treatment satisfaction, and quality of life in Asia-Pacific women with postmenopausal osteoporosis.

Purpose This study aimed to describe the impact of gastrointestinal (GI) events on patient-reported outcomes and health care resource use among Asia-Pacific women with postmenopausal osteoporosis.

Methods The MUSIC OS-AP study included an observational cohort study of postmenopausal women with osteoporosis. Women were classified as untreated or treated, with treated patients further classified as new or experienced users. Adherence was measured by the Adherence Evaluation of Osteoporosis treatment (ADEOS) questionnaire, treatment satisfaction by the Osteoporosis Patient Satisfaction Questionnaire (OPSAT) while general health-related and osteoporosis-specific quality of life were measured by the European Quality of Life-5 Dimensions (EQ-5D) questionnaire and the Osteoporosis Assessment Questionnaire (OPAQ), respectively. The association of GI events with these outcomes was determined by covariate-adjusted regression analysis of least squares mean differences in the scores of treated patients with and without GI events. Resource utilization was measured as the number of physician visits over the past 3 months, and multivariate regression analysis was used to assess the association of GI events with the likelihood of a visit.

Results The GI event profile, quality of life scores, and resource use were numerically similar in untreated and treated women. The rate of adherence among treated women was higher in experienced than in new users. As indicated by mean scores, experienced users had better quality of life and slightly higher treatment satisfaction and fewer physician visits than new users. Except for adherence in new users, all measures were similarly adversely affected by GI events in both new and experienced users.

Conclusions GI events decreased adherence, treatment satisfaction, and quality of life in Asia-Pacific women with postmenopausal osteoporosis.

Keywords Osteoporosis · Postmenopausal · Gastrointestinal diseases · Patient satisfaction · Quality of life · Medication adherence

Introduction

The incidence of osteoporotic hip fracture has risen 2–3-fold in Asia over the past few decades [1]. It is now recognized that
the prevalence of osteoporosis in older women (i.e., aged ≥50) living in Asia-Pacific countries is comparable to that in European and North American populations [2]. A scarcity of diagnostic instruments (e.g., dual-energy x-ray absorptiometers) and lack of epidemiologic and economic data have prevented many of these countries from developing official guidelines for diagnosis and treatment of osteoporosis and raising public awareness of the disease [1]. As a result, the burden of osteoporosis in the Asia-Pacific region is not well documented.

In particular, the gastrointestinal (GI) events that are common among users of osteoporosis therapy in US [3] and European [4, 5] populations are virtually uncharacterized in patients in the Asia-Pacific region. Such events, or use of medications suggesting their occurrence, have been shown to be associated with reduced adherence (both compliance and persistence) to treatment [6–11] and low treatment satisfaction [12–14]. Increased health care resource use has also been documented among patients with osteoporosis treatment-related GI events [15, 16]. However, such associations have not been assessed in Asian or Australian populations.

The Medication Use Patterns, Treatment Satisfaction, and Inadequate Control of Osteoporosis Study in the Asia-Pacific Region (MUSIC OS-AP) was designed to address this information gap. The primary objectives of MUSIC OS-AP were (i) to describe the frequency of GI events among postmenopausal women receiving pharmacologic treatment for osteoporosis and (ii) to assess the association between GI events and adherence, treatment satisfaction, health-related quality of life, and health care resource utilization.

Methods

Study design

Details of the design of MUSIC OS-AP are given in a previous publication [17]. The study was conducted in five Asia-Pacific countries: Australia, New Zealand, Taiwan, Korea, and India. This manuscript describes patient-reported outcomes from the baseline assessment in the prospective study.

Study sample

Patients were eligible for enrollment in the prospective study if they were postmenopausal women, at least 50 years of age, had osteoporosis in their physician’s judgment (with or without a BMD test), and provided informed consent. Patients were excluded if they had been diagnosed with Parkinson’s disease or any other neuromuscular disease or Paget’s disease, were currently treated with any injected medication for osteoporosis, had been switched between oral pharmacologic osteoporosis medications within the past 3 months, or were currently or formerly (past 90 days) enrolled in a clinical trial.

Study definitions

Enrollees were classified as either untreated or treated, with treated patients further classified as new or experienced users. New users were patients who had been receiving oral pharmacologic therapy for less than 3 months, and experience users were patients receiving the same oral pharmacologic therapy for at least 3 months prior to enrollment. Oral pharmacologic therapies included bisphosphonates (e.g., alendronate, risedronate, and ibandronate), calcitonin, strontium ranelate, and selective estrogen-receptor modulators (raloxifene and bazedoxifene).

GI events were defined as the following clinical symptoms: heartburn/acid reflux, upset stomach/indigestion, nausea/vomiting, pain behind the breastbone, pain on swallowing or food sticking, stomach pain above or below the navel, diarrhea or constipation, and bloating.

Patient-reported race was classified as Caucasian, East Asian, or West Asian. Caucasian was defined as European, Mediterranean, Middle Eastern, or North African Descent. East Asian was defined as Chinese, Korean, Japanese, or Taiwanese. West Asian was defined as Indian or Pakistani.

Study outcomes

GI events were assessed by asking patients whether they had experienced any of the above-listed symptoms in the past 6 months. Answers were indicated with yes/no check boxes for each symptom.

Adherence and treatment satisfaction were assessed in treated patients only. Adherence was measured by the Adherence Evaluation of Osteoporosis treatment (ADEOS) questionnaire [18] and defined as a score of ≥20 out of 22. The questions are not temporally constrained. Patients with missing answers were excluded from the analyses of adherence. Treatment satisfaction was measured with the Osteoporosis Patient Treatment Satisfaction Questionnaire (OPSAT-Q) [19]. The OPSAT-Q consists of 16 items on 4 subscales (convenience, confidence with daily functioning, overall satisfaction, and side effects). Subscale scores are used to create a composite satisfaction score that ranges from 0 to 100, with higher scores indicating greater treatment satisfaction. The questions have no temporal frame of reference.

Quality of life and health care resource use were assessed in both untreated and treated patients. General health-related quality of life was measured with the EuroQol-5D-3L [20]. The EuroQol-5D has two components: a utility score (scale 0 to 1.0, where 1.0 is defined as full health, zero as death) and a visual analog scale (VAS; scale 0–100, 100 being best imaginable health). The utility score comprises five dimensions.
Demographic and clinical characteristics and patient-reported outcomes were analyzed descriptively. Continuous variables were reported as means and standard deviations and categorical variables as numbers and percentages.

The effect of GI events on patient-reported outcomes at baseline was assessed in treated patients by calculating clinical variables as numbers and percentages. Results were reported as means and standard deviations and categorically as numbers and percentages. The time frame of the questionnaire is the previous 2 weeks. Analyses of the physical function domain have suggested that a difference of 10 points would be clinically meaningful at the individual patient level [24]. Health care resource utilization was measured as the number of osteoporosis-related primary care and specialist physician visits over the past 3 months.

All questionnaires were made available in the local language of the participating clinics (see the original MUSIC OS-AP publication for more details [17]).

Statistical analysis

A total of 300 untreated patients were enrolled in the study (Table 1). Their mean age was 63.0 years, and the majority (56.7%) were West Asian. Approximately one fifth had a history of osteoporotic fracture (17.7%) or a fall within the previous 12 months (21.7%). Most untreated patients (61.3%) reported experiencing a GI event in the past 6 months.

Mean scores on the EQ-5D-3L were 0.70 for the utility measure and 66.8 for the VAS (Table 1). Mean scores on the OPAQ-SV were 66.7 for physical function, 65.1 for emotional status, and 59.1 for back pain. Untreated patients reported an average of 1.5 osteoporosis-related primary care visits and 1.6 osteoporosis-related specialist visits in the previous 3 months.

Characteristics of treated patients

A total of 3286 treated patients were enrolled in the study (Table 1). The mean age of treated patients was 65.4 years, and there was a nearly equal representation of East Asians (45.0%) and West Asians (41.1%). Approximately one fifth had a history of osteoporotic fracture (21.5%) or had had a fall within the past 12 months (18.0%). Most treated patients (59.9%) reported having GI events in the previous 6 months. In the past 12 months, 88.1% of all treated patients reported using a bisphosphonate while 13.1% reported using a non-bisphosphonate (Table 1).

Only 38.1% of the treated patients qualified as adherent with their treatment, and the mean satisfaction score was 79.1 (Table 1). Mean scores on the EQ-5D-3L were 0.71 for the utility measure and 67.6 for the VAS. Mean scores on the OPAQ-SV were 67.6 for physical function, 65.4 for emotional status, and 65.7 for back pain. Treated patients reported an average of 1.5 osteoporosis-related primary care visits and 1.5 osteoporosis-related specialist visits in the previous 3 months.

Among the treated patients, 1416 were new users and 1870 were experienced users of osteoporosis treatment (Table 1). New users were younger (mean age 62.9) than experienced users (mean age 67.3), and the majority of them were West Asian (68.0%), whereas the majority of experienced users were East Asian (59.2%). A history of osteoporotic fracture was more prevalent among experienced users (25.8%) than new users (15.9%). More experienced users (39.6%) were adherent with treatment than new users were (33.6%), but...
their satisfaction levels were approximately equal. All quality of life scores were better in experienced users than in new users, and osteoporosis-related resource use was less frequent in experienced users than in new users (Table 1).

### Table 1  Demographic and clinical characteristics of the study population

|                                      | Untreated (N = 300) | All treated patients (N = 3286) | New users (N = 1416) | Experienced users (N = 1870) |
|--------------------------------------|---------------------|---------------------------------|----------------------|-----------------------------|
| Age, mean (SD) years                 | 63.0 (9.3)          | 65.4 (9.5)                      | 62.9 (9.5)           | 67.3 (9.0)                  |
| Age at menopause, mean (SD) years    | 48.5 (4.8)          | 47.9 (5.4)                      | 47.2 (5.6)           | 48.4 (5.1)                  |
| Racea                                |                     |                                 |                      |                             |
| Caucasian                            | 36 (12.0)           | 454 (13.8)                      | 80 (5.6)             | 374 (20.0)                  |
| East Asian                           | 97 (32.3)           | 1479 (45.0)                     | 372 (26.3)           | 1107 (59.2)                |
| West Asian                           | 167 (56.7)          | 1352 (41.1)                     | 963 (68.0)           | 389 (20.8)                  |
| Other                                | 0 (0.0)             | 1 (0.03)                        | 1 (0.07)             | 0 (0.0)                     |
| History of OP fracture               | 53 (17.7)           | 707 (21.5)                      | 225 (15.9)           | 482 (25.8)                  |
| Falls in the past 12 months          | 65 (21.7)           | 593 (18.0)                      | 262 (18.5)           | 331 (17.7)                  |
| Gl events in the past 6 months       | 184 (61.3)          | 1967 (59.9)                     | 814 (57.5)           | 1153 (61.7)                |
| Upper GI                             | 154 (51.3)          | 1658 (50.5)                     | 720 (50.8)           | 938 (50.2)                  |
| Heartburn/acid reflux                | 103 (34.3)          | 1098 (33.4)                     | 455 (32.1)           | 643 (34.4)                  |
| Upset stomach/indigestion           | 75 (25.0)           | 816 (24.8)                      | 363 (25.6)           | 453 (24.2)                  |
| Nausea/vomiting                      | 44 (14.7)           | 377 (11.5)                      | 152 (10.7)           | 225 (12.0)                  |
| Pain behind the breastbone           | 23 (7.7)            | 375 (11.4)                      | 172 (12.1)           | 203 (10.9)                  |
| Pain on swallowing or food sticking  | 17 (5.7)            | 227 (6.9)                       | 102 (7.2)            | 125 (6.7)                   |
| Stomach pain above the navel         | 28 (9.3)            | 260 (7.9)                       | 107 (7.6)            | 153 (8.2)                   |
| Lower GI                             | 96 (32.0)           | 863 (26.3)                      | 347 (24.5)           | 516 (27.6)                  |
| Diarrhea or constipation             | 86 (28.7)           | 799 (23.7)                      | 305 (21.5)           | 474 (25.3)                  |
| Stomach pain below the navel         | 26 (8.7)            | 227 (6.9)                       | 93 (6.6)             | 134 (7.2)                   |
| Bloating                             | 68 (22.7)           | 687 (20.9)                      | 264 (18.6)           | 423 (22.6)                  |
| Osteoporosis medication              |                     |                                 |                      |                             |
| Bisphosphonates                      |                     |                                 |                      |                             |
| Alendronic acid                      | –                   | 1695 (51.6)                     | 371 (26.2)           | 867 (46.4)                  |
| Etidronic acid                       | –                   | 2 (0.06)                        | 0 (0.0)              | 2 (0.11)                    |
| Ibandronic acid                      | –                   | 339 (10.3)                      | 73 (5.2)             | 162 (8.7)                   |
| Pamidronic acid                      | –                   | 1 (0.03)                        | 0 (0.0)              | 1 (0.05)                    |
| Risedronic acid                      | –                   | 872 (26.5)                      | 129 (9.1)            | 533 (28.5)                  |
| Non-bisphosphonates                  |                     |                                 |                      |                             |
| Bazedoxifene                         | –                   | 66 (2.0)                        | 19 (1.3)             | 47 (2.5)                    |
| Calcitonin                           | –                   | 7 (0.21)                        | 2 (0.14)             | 5 (0.27)                    |
| Denosumab                            | –                   | 1 (0.03)                        | 0 (0.0)              | 1 (0.05)                    |
| Raloxifene                           | –                   | 299 (9.1)                       | 44 (3.1)             | 255 (13.6)                  |
| Strontium ranelate                   | –                   | 55 (1.7)                        | 7 (0.49)             | 48 (2.6)                    |
| Teriparatide                         | –                   | 4 (0.12)                        | 1 (0.07)             | 3 (0.16)                    |
| Adherenceb                           | –                   | 943 (38.1)                      | 202 (33.6)           | 741 (39.6)                  |
| OP5-SD-5L score, mean (SD)c          | –                   | 79.1 (12.9)                     | 78.1 (13.7)          | 79.5 (12.6)                 |
| OP5-SD-5L utility score, mean (SD)d  | 0.70 (0.28)         | 0.71 (0.28)                     | 0.62 (0.30)          | 0.77 (0.24)                 |
| OP5-SD-5L VAS score, mean (SD)d      | 66.8 (18.7)         | 67.6 (18.5)                     | 62.8 (17.6)          | 71.2 (18.3)                 |
| OPAQ-SV scores, mean (SD)d          |                     |                                 |                      |                             |
| Physical function                    | 66.7 (18.6)         | 67.6 (19.9)                     | 59.5 (20.0)          | 73.8 (17.4)                 |
| Emotional status                     | 65.1 (21.6)         | 65.4 (19.5)                     | 62.4 (19.8)          | 67.7 (18.9)                 |
| Back pain                            | 59.1 (28.9)         | 65.7 (26.7)                     | 58.8 (27.3)          | 70.9 (25.0)                 |
| Primary care visits, mean (SD)f      | 1.5 (0.95)          | 1.5 (0.93)                      | 1.7 (1.10)           | 1.4 (0.75)                  |
| Specialist visits, mean (SD)f        | 1.6 (0.82)          | 1.5 (0.92)                      | 1.7 (1.01)           | 1.4 (0.84)                  |

---

*EQ-SD-5L* European Quality of Life-5 Dimensions, *GI* gastrointestinal, *OP* osteoporosis, *OPAQ-SV* Osteoporosis Assessment Questionnaire, *OPSAT-Q* Osteoporosis Patient Satisfaction Questionnaire, *SD* standard deviation, *VAS* visual analog scale

Values are presented as N (%) unless otherwise indicated

a Caucasian was defined as European, Mediterranean, Middle Eastern, or North African Descent. East Asian was defined as Chinese, Korean, Japanese, or Taiwanese. West Asian was defined as Indian or Pakistani. Other included only those identifying as New Zealand Maori

b Calculated for patients responding to this survey question. Total N = 2471 (experienced users = 1869; new users = 602)

c Calculated for patients responding to this survey question. Total N = 2529 (experienced users = 1867; new users = 662)

d Averaged over all available data. Missing data constituted <0.5% of patients
e Averaged among patients with any primary care visits (N = 51, 634, 291, and 343, respectively) or specialist visits (N = 96, 1255, 506, and 749, respectively)
Effect of GI events on patient-reported outcomes

Differences in least-squares mean scores between treated patients with and without GI events are shown in Table 2. Least squares mean differences associated with GI events in all treated patients were −0.348 for the adherence score, −6.940 for the OPSAT score, −0.092 for the EQ-5D utility score, −4.614 for the EQ-5D visual analog scale score, −3.663 for the OPAQ physical function score, −4.435 for the OPAQ emotional status score, and −8.183 for the OPAQ back pain score. All these differences met the criterion for statistical significance. Expressed as a percentage of the total scale for each outcome, the differences associated with GI events ranged from 1.6% for adherence to 9.2% for the EQ-5D utility score. Except for adherence in new users, all of these measures were significantly adversely affected by GI events in both new and experienced users (Table 2). The decrement in treatment satisfaction associated with GI events was significantly greater in new users than in experienced users (CI for new users −10.45 to −6.834; CI for experienced users −6.350 to −4.126; Table 2). For all other outcomes, new and experienced users were affected to a similar extent.

In regression analyses of resource use (Table 3), experienced users with GI events were 43% more likely to have a primary care visit than were those without GI events (OR 1.43, 95% CI 1.08–1.9). GI events were not associated with primary care visits in new users or all treated patients and had no association with specialist visits.

Discussion

This baseline assessment of the MUSIC OS-AP population showed that GI events decreased adherence to treatment, treatment satisfaction, and quality of life, as reported by Asia-Pacific women receiving pharmacologic treatment for postmenopausal osteoporosis. GI events did not affect osteoporosis-related resource use.

There is little information on the effect of GI events on adherence to osteoporosis therapy in the Asia-Pacific region. In a study of 208 Japanese osteoporosis patients (1.5% male), patient-reported side effects were the primary driver of non-compliance with alendronate or risedronate [25]. Another study of 1307 Japanese patients (15.1% male) receiving their first bisphosphonate at a university hospital found that switching therapies because of adverse effects was associated with reduced persistence and that discontinuation of the first drug due to adverse effects was associated with higher rates of discontinuation of the second drug for the same reason (hazard ratio 4.2, 95% CI 2.1–8.4) [26]. However, neither of these studies limited the analysis of adverse events to GI events. Previous US studies have reported the effects of GI events on adherence among osteoporosis patients; however, these studies did not assess the effect of GI events on adherence using the ADEOS questionnaire [6, 10, 11, 13]. Among these US studies, the Prospective Observational Scientific Study Investigating Bone Loss Experience (POSSIBLE) study is best suited for comparison to MUSIC OS [13]. In the US cohort of POSSIBLE, women reporting GI side effects were more likely to discontinue therapy at both 6 and 12 months [13]. However, discontinuation is not directly comparable to the medication-taking behaviors assessed by the ADEOS questionnaire. Such behaviors were assessed using ADEOS by the MUSIC OS study in Europe and Canada (MUSIC OS-EU), which found that treated osteoporosis patients with GI events had lower ADEOS scores than those without GI events (adjusted least squares mean difference −0.43; P < 0.001) [27]. This result is consistent with the findings of the MUSIC OS-AP study (adjusted least squares mean difference −0.348). The MUSIC OS-AP study is unique in that it directly assesses the association of GI events with adherence to oral osteoporosis therapies in the Asia-Pacific region using ADEOS scores.

The relationship of GI events to treatment satisfaction was assessed with the OPSAT questionnaire in a study of 4220 Korean women taking oral bisphosphonates [28]. The mean composite OPSAT score was 75.3 in non-users of acid-related medications versus 70.8 in users of such medications. Taking acid-related medication use as a proxy for GI symptoms, these data are quite similar to ours. In MUSIC OS-AP, the mean composite OPSAT score at baseline was 79.1 among treated patients, and GI events were shown to reduce this score by 6.9 points. We identified only one other study from Asia reporting the effects of GI symptoms on treatment satisfaction. Chung et al. used a crossover design to assess patient preferences for monthly ibandronate versus weekly risedronate in 365 Korean women [29]. In this study, less stomach discomfort and more tolerable side effects were among the patient-reported reasons for a preference for the ibandronate regimen. In the MUSIC OS-EU study, covariate-adjusted OPSAT scores of experienced users of treatment for osteoporosis were 5.68 points lower in those with versus without GI events [27], a decrement comparable to that seen in experienced users in the current study (−5.24). In the POSSIBLE-US cohort, women experiencing a GI side effect at month 6 had lower global treatment satisfaction scores (assessed by the Treatment Satisfaction Questionnaire for Medication) than those without GI side effects [13].

In MUSIC OS-AP, both general and osteoporosis-specific quality of life were reduced by GI events. Least-squares mean differences associated with GI events were −0.092 for the EQ-5D utility score and −3.663 for the OPAQ physical function score. Although both values were statistically significant, only the former met the threshold of the minimal clinically
important difference (see the “Methods” section). Previous studies of the relationship of GI events and quality of life are few. In one of the Korean studies described above, osteoporosis-specific quality of life was reduced in patients using acid-related medications (a proxy for GI events); the quality of life domain scores on the OPSAT questionnaire were 62.7 in users and 66.8 in non-users of acid-related medications ($P < 0.001$) [28]. Similar to the results reported in MUSIC OS-AP, EQ-5D and OPAQ-SV physical function scores were significantly reduced in patients with versus without GI events in the MUSIC OS-EU study [27]. In contrast, in POSSIBLE-US, EQ-5D utility scores measured at month 6 were not significantly different between patients with and without GI side effects [13]. The MUSIC OS-AP study included untreated patients at the baseline assessment, 18% of whom had a history of osteoporotic fracture. This fracture rate is somewhat lower than the expected lifetime fracture risk of 30 to 40% for older women [30–32]. The GI event rate in this population (61%) is consistent with previous reports that GI symptoms are common in Asian adults, regardless of osteoporosis treatment [33–36]. The EQ-5D-3L utility and VAS scores in untreated osteoporosis patients in MUSIC OS-AP (0.70 and 66.8, respectively) were lower than those in the published population norms for women in Australia (0.87 utility) [37], New Zealand (0.85 and 81.2, respectively) [38], Taiwan (74.3 VAS) [39], and Korea (0.89 and 78.7, respectively) [38]. GI event rates,

| Table 2 Least-squares mean differences between treated patients with and without GI events at baseline |
|---------------------------------------------------------------|
| With GI events: | Without GI events: | LS mean difference | 95% CI   | $P$ value |
| LS mean | LS mean |
|----------------|----------------|--------------------|---------|-----------|
| Adherence                   |                 |                    |         |           |
| All treated | 18.155 | 18.503 | $-0.348$ | $-0.591$, $-0.104$ | 0.005 |
| New users | 17.634 | 17.825 | $-0.191$ | $-0.609$, 0.227 | 0.370 |
| Experienced users | 18.676 | 19.181 | $-0.504$ | $-0.750$, $-0.258$ | <0.001 |
| OPSAQ-Q score                |                 |                    |         |           |
| All treated | 76.323 | 83.263 | $-6.940$ | $-8.007$, $-5.874$ | <0.001 |
| New users | 74.020 | 82.662 | $-8.643$ | $-10.45$, $-6.834$ | <0.001 |
| Experienced users | 76.437 | 83.864 | $-5.238$ | $-6.350$, $-4.126$ | <0.001 |
| EQ-5D-3L utility score      |                 |                    |         |           |
| All treated | 0.707 | 0.799 | $-0.092$ | $-0.109$, $-0.074$ | <0.001 |
| New users | 0.674 | 0.777 | $-0.103$ | $-0.129$, $-0.077$ | <0.001 |
| Experience users | 0.740 | 0.821 | $-0.080$ | $-0.103$, $-0.057$ | <0.001 |
| EQ-5D-3L VAS score          |                 |                    |         |           |
| All treated | 68.120 | 72.734 | $-4.614$ | $-5.795$, $-3.433$ | <0.001 |
| New users | 67.862 | 72.341 | $-4.479$ | $-6.235$, $-2.723$ | <0.001 |
| Experienced users | 68.378 | 72.345 | $-4.748$ | $-6.307$, $-3.189$ | <0.001 |
| OPAQ-SV physical function score | 67.874 | 71.536 | $-3.663$ | $-4.763$, $-2.563$ | <0.001 |
| New users | 65.798 | 69.783 | $-3.985$ | $-5.621$, $-2.349$ | <0.001 |
| Experienced users | 69.950 | 73.290 | $-3.340$ | $-4.793$, $-1.888$ | <0.001 |
| OPAQ-SV emotional status score | 63.707 | 68.141 | $-4.435$ | $-5.690$, $-3.180$ | <0.001 |
| New users | 62.759 | 66.132 | $-3.373$ | $-5.240$, $-1.507$ | <0.001 |
| Experienced users | 64.654 | 70.150 | $-5.496$ | $-7.153$, $-3.839$ | <0.001 |
| OPAQ-SV back pain score     |                 |                    |         |           |
| All treated | 66.572 | 74.754 | $-8.183$ | $-9.888$, $-6.478$ | <0.001 |
| New users | 63.692 | 72.616 | $-8.924$ | $-11.46$, $-6.388$ | <0.001 |
| Experienced users | 69.451 | 76.893 | $-7.442$ | $-9.693$, $-5.191$ | <0.001 |

Scores were adjusted by multivariate regression for the following variables: age, age at menopause, highest level of education, country, BMI, history of GI events, user status (among all treated patients), number of previous fractures, number of previous falls, predominant treatment, hours of physical exercise per week, presence of at least one risk factor, presence of comorbidities, and interactions between history of GI events and treatment group. CI confidence interval, EQ-5D-3L European Quality of Life-5 Dimensions, GI gastrointestinal, LS least squares, OPAQ-SV Osteoporosis Assessment Questionnaire, OPSAQ-Q Osteoporosis Patient Satisfaction Questionnaire, VAS visual analog scale.
quality of life scores, and resource use were numerically similar in untreated and treated women.

The results of the current MUSIC OS-AP analysis improve upon previous studies in several ways. First, MUSIC OS-AP assessed quality of life and treatment satisfaction separately in patients with or without GI events, a design element missing from earlier studies of this question [12, 14]. Second, our analyses were adjusted for demographic and clinical covariates, such that the results indicate an effect of GI events on adherence, quality of life, and treatment satisfaction independent of confounder variables. Finally, to our knowledge, MUSIC OS-AP is the first study to assess directly the association of GI events with adherence, quality of life, and treatment satisfaction in osteoporotic patients from the Asia-Pacific region.

Despite these strengths, the current analysis is subject to several important limitations. First, due to the design of the study as a patient survey, the accuracy of the findings is limited by patient recall and potentially affected by reporting bias. Second, the least-squares mean differences were not adjusted for adherence, so some patients may have had GI events not associated with treatment. Third, patients were not required to report the severity of the GI events; in fact, GI events typically considered severe (e.g., those involving bleeding or perforation) were not included in the patient questionnaire. Thus, our results reflect primarily the experience of patients with mild to moderate GI symptoms. Fourth, the lack of statistical comparisons of untreated and treated patients precludes drawing conclusions regarding the relationship between treatment and GI event rates and quality of life. Fifth, the data were pooled from culturally and demographically different countries and therefore reflect the average effect within potentially disparate data. Finally, lack of information about the minimal clinically important difference on the ADEOS and OPSAT questionnaires prevents assessment of the clinical relevance of the effect sizes reported here, and some of the observed differences in quality of life, although statistically significant, may not have been clinically important.

In conclusion, the baseline assessment of MUSIC OS-AP showed that GI events were common in postmenopausal women with osteoporosis in the Asia-Pacific region, occurring in approximately 60% of both treated and untreated patients. Among women treated for osteoporosis, GI events were associated with decreased adherence, lower treatment satisfaction, and worse quality of life. Treatment satisfaction was affected to a greater extent in new users of osteoporosis treatment versus experienced users. These results suggest that GI events should be given consideration during the clinical management of osteoporotic women in the Asia-Pacific region.

Acknowledgements The authors thank the following MUSIC OS-AP site investigators: in Taiwan, Ning-Sheng Lai, Yang-Hwei Tsuang, Horng-Chaung Hsu, James Cheng-Chung Wei, Shao-Keh Hsu, Hongsen Chiang, Ting-Kuo Chang, Kang Lu, and Chung-Hwan Chen; in India, Harvinder Singh Chhabra, Rajesh Malhotra, Arun Bhanot, Lalit Duggal, Jyotsna Oak, Vaishali Desh Mulk, Parag Sancheti, Bharat Dave, Vikash Kapor, An Roy, Thomas Paul, Mala Dharmalingam, Rakesh Rajput, Abhay Nene, and Harshad Shah; in Australia and New Zealand, Graeme Jones, Gustavo Duque, Nigel Gilchrist, Ego Seeman, Jeremy Allen, Lyn March, Fred Delooze, John Wark, Robert Will, Michael Campbell, and Charles Inderjeeth; in South Korea, Moo Il Kang, Hyun Koo Yoon, Yoon-Sok Chung, Dongwon Byun, In Ju Kim, Deog-Yoon Kim, Dong Jin Chung, Sung-hee Choi, Seong Bin Hong, Yumie Rhee, Jung hee Kim, Kyong-Chol Kim, Dong-Hyeok Shin, Seon-Hwa Lee, and Choon-Hee Chung.

The authors thank Melissa Stauffer, PhD, and Anna Kaufman, MPH, in collaboration with ScribCo, for the medical writing assistance.

This study was funded by Merck & Co., Inc., Kenilworth, NJ, USA.

Compliance with ethical standards All sites completed ethics reviews according to their local ethics board requirements.

Conflict of interest A. Modi, XY, and S. Sen are employees of Merck & Co., Inc. A. Modi and S. Sen own stock in the company. S. Sujan was an employee of Merck & Co., Inc. and owned stock in the company at the time of the study. PRE has received research funding from Merck & Co., Inc., Amgen, Novartis, GlaxoSmithKline, and Eli Lilly and honoraria from Merck & Co., Inc., Amgen, and ViIV Healthcare. SB is employed by Optum and has received financial remuneration from Merck & Co., Inc. to participate in the study. SML, YKM, and A. Mithal have no conflicts of interest to report.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
References

1. Mithal A, Dhingra V, Lau E (2009) The Asian Audit-Epidemiology, costs and burden of osteoporosis in Asia 2009: A report of International Osteoporosis Foundation 2009, https://www.iofbonehealth.org/sites/default/files/PDFs/Audit%20Asia/AsianRegionalAudit_2009.pdf. Accessed 15 Feb 2015

2. Wade SW, Strader C, Fitzpatrick LA, Anthony MS, O’Malley CD (2014) Estimating prevalence of osteoporosis: examples from industrialized countries. Arch Osteoporos 9:182. doi:10.1007/s11657-014-0182-3

3. Tosteson AN, Grove MR, Hammond CS, Moncur MM, Ray GT, Hebert GM, Pressman AR, Ettinger B (2003) Early discontinuation of treatment for osteoporosis. Am J Med 115:209–216

4. Ringe JD, Moller G (2009) Differences in persistence, safety and efficacy of generic and original branded once weekly bisphosphonates in patients with postmenopausal osteoporosis: 1-year results of a retrospective patient chart review analysis. Rheumatol Int 30:213–221. doi:10.1007/s00296-009-0940-5

5. Payer J, Cierny D, Killinger Z, Sulkova I, Behuliak M, Celec P (2009) Preferences of patients with post-menopausal osteoporosis treated with bisphosphonates—the VIVA II study. J Int Med Res 37:1225–1229

6. Lo JC, Pressman AR, Omar MA, Ettinger B (2006) Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 17:922–928. doi:10.1007/s00198-006-0085-2

7. Rossini M, Bianchi G, Di Munno O, Giannini S, Minisola S, Simaglia L, Adami S (2006) Determinants of adherence to osteoporosis treatment in clinical practice. Osteoporos Int 17:914–921. doi:10.1007/s00198-006-0073-6

8. Penning-van Beest FJ, Erkens JA, Olson M, Herings RM (2008) Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis. Curr Med Res Opin 24:1337–1344. doi:10.1185/030079908X297358

9. Gallagher AM, Riebrock S, Olson M, van Staa TP (2008) Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res 23:1569–1575. doi:10.1359/jbmr.080510

10. Modi A, Siris S, Yang X, Fan CP, Sajjan S (2015) Association between gastrointestinal events and persistence with osteoporosis therapy: analysis of administrative claims of a U.S. managed care population. J Manag Care Spec Pharm 21:499. doi:10.18553/jmcp.2015.21.6.499

11. Yun H, Curtis JR, Guo L, Kilgore M, Muntrer P, Saag K, Matthews R, Morrisey M, Wright NC, Becker DJ, Delzell E (2014) Patterns and predictors of osteoporosis medication discontinuation and switching among Medicare beneficiaries. BMC Musculoskelet Disord 15:112. doi:10.1186/1471-2474-15-112

12. Binkley N, Martens MG, Silverman SL, Derman RJ, Greenwald M, Kohles JD, Bachmann GA (2009) Improved GI tolerability with monthly ibandronate in women previously using weekly bisphosphonates. South Med J 102:486–492. doi:10.1097.SMJ.0b013e3181e8d0dd

13. Woo C, Gao G, Wade S, Hochberg MC (2010) Gastrointestinal side effects in postmenopausal women using osteoporosis therapy: 1-year findings in the POSSIBLE US study. Curr Med Res Opin 26:1003–1009. doi:10.1185/03007991003633603

14. Turbi C, Herrero-Beaumont G, Acebes JC, Torrijos A, Grana J, Miguez RF, Sacristan J, Marin F (2004) Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 26:245–256

15. Blumentals WA, Harris ST, Cole RE, Huang L, Silverman SL (2009) Risk of severe gastrointestinal events in women treated with monthly ibandronate or weekly alendronate and risedronate. Ann Pharmacother 43:577–585. doi:10.1345/aph.1L555

16. Landfeldt E, Lang A, Robbins S, Strom O (2011) Gastrointestinal tolerability and patterns of switching in patients treated for primary osteoporosis: the Swedish adherence register analysis (SARA). Calcif Tissue Int 89:234–245. doi:10.1007/s00223-011-9511-3

17. Modi A, Ebeling P, Lee MS, Min YK, Mithal A, Yang X, Sajjan S (2015) Medication use patterns, treatment satisfaction, and inadequate control of osteoporosis study in the Asia-Pacific region (MUSIC OS-AP): design of a multinational, prospective, observational study examining the impact of gastrointestinal events on osteoporosis management in postmenopausal women. Bone Rep 3:61–66. doi:10.1016/j.bonr.2015.09.002

18. Breuil V, Cortet B, Cotte FE, Arnould B, Dias-Barbosa C, Gaudin AF, Regnault A, Roborel de Climens A, Legrand E (2012) Validation of the adherence evaluation of osteoporosis treatment (ADEOS) questionnaire for osteoporotic post-menopausal women. Osteoporos Int 23:445–455. doi:10.1007/s00198-011-1555-8

19. Flood EM, Beusterien KM, Green H, Shikirai R, Baran RW, Ammonkar MM, Cella D (2006) Psychometric evaluation of the osteoporosis patient treatment satisfaction questionnaire (OPSAT-Q), a novel measure to assess satisfaction with bisphosphonate treatment in postmenopausal women. Health Qual Life Outcomes 4:42. doi:10.1186/1477-7525-4-42

20. Rabin R, de Charro F (2001) EQ-5D: a measure of health status from the EuroQol group. Ann Med 33:337–343

21. Walters SJ, Brazier JE (2005) Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 14:1523–1532

22. Sullivan PW, Lawrence WF, Ghushchyan V (2005) A national catalog of preference-based scores for chronic conditions in the United States. Med Care 43:736–749

23. Silverman S (2000) The osteoporosis assessment questionnaire (OPAQ): a reliable and valid disease-targeted measure of health-related quality of life (HRQOL) in osteoporosis. Qual Life Res 9:767–774. doi:10.1023/A:1008934208764

24. Nixon A, Kerr C, Doll H, Naegeli AN, Shingler SL, Breheny K, Burge R, Gold DT, Silverman S (2014) Osteoporosis assessment questionnaire-physical function (OPAQ-PF): a psychometrically validated osteoporosis-targeted patient reported outcome measure of daily activities of physical function. Osteoporos Int 25:1775–1784. doi:10.1007/s00198-014-2695-4

25. Kamatari M, Koto S, Ozawa N, Urao C, Suzuki Y, Akasaka E, Yamagimoto K, Sakota K (2007) Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate. J Bone Miner Metab 25:302–309. doi:10.1007/s00774-007-0768-6

26. Ideguchi H, Ohno S, Takase A, Ueda A, Ishigatsubo Y (2008) Outcomes after switching from one bisphosphonate to another in 146 patients at a single university hospital. Osteoporos Int 19:1777–1783. doi:10.1007/s00198-008-0618-y

27. Modi A, Sen S, Adachi JD, Adami S, Cortet B, Cooper AL, Geusens P, Mellstrom D, Weaver J, van den Bergh JP, Nguyen AM, Sajjan S, Group M-OS (2016) Gastrointestinal symptoms and association with medication use patterns, adherence, treatment satisfaction, quality of life, and resource use in osteoporosis: baseline results of the MUSIC-OS study. Osteoporos Int 27:1227–1238. doi:10.1007/s00198-015-3388-3

28. Oh KW, Kim DY, Lee YS, Kang MI (2012) Osteoporosis patient treatment satisfaction questionnaire in postmenopausal women intermittently treated with oral bisphosphonates: the BRAVO study. J Bone Miner Metab 30:359–366. doi:10.1007/s00774-011-0326-0

29. Chung YS, Lim SK, Chung HY, Lee IK, Park IH, Kim GS, Min YK, Kang MI, Chung DJ, Kim YK, Choi WH, Shong MH, Park JH, Byun DW, Yoon HK, Shim CS, Lee YS, Kwon NH (2009) Comparison of monthly ibandronate versus weekly risedronate in
preference, convenience, and bone turnover markers in Korean postmenopausal osteoporotic women. Calcif Tissue Int 85:389–397. doi:10.1007/s00223-009-9294-y

30. Watts NB, Bilezikian JP, Camacho PM, Greenspan SL, Harris ST, Hodgson SF, Kleerekoper M, Luckey MM, McClung MR, Pollack RP, Petak SM (2010) American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the diagnosis and treatment of postmenopausal osteoporosis. Endocr Pract 16(Suppl 3):1–37

31. MacLean C, Newberry S, Maglione M, McMahon M, Ranganath V, Suttoop M, Mojica W, Timmer M, Alexander A, McNamara M, Desai SB, Zhou A, Chen S, Carter J, Tringale C, Valentine D, Johnsen B, Grossman J (2008) Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med 148:197–213

32. Kanis JA, On behalf of the World Health Organization Scientific Group (2007) Assessment of osteoporosis at the primary healthcare level. World Health Organization Collaborating Centre for metabolic bone diseases. University of Sheffield, United Kingdom

33. Chang FY, Chen PH, Wu TC, Pan WH, Chang HY, Wu SJ, Yeh NH, Tang RB, Wu L, James FE (2012) Prevalence of functional gastrointestinal disorders in Taiwan: questionnaire-based survey for adults based on the Rome III criteria. Asia Pac J Clin Nutr 21:594–600

34. Goh KL (2007) Changing trends in gastrointestinal disease in the Asia-Pacific region. J Dig Dis 8:179–185. doi:10.1111/j.1751-2980.2007.00304.x

35. Guarner F, Lázaro, Gascón, Royo, Eximan, Herrero (2008) Map of digestive disorders & diseases. World Gastroenterology Organisation. http://www.worldgastroenterology.org/assets/downloads/pdf/wdhd/2008/events/map_of_digestive_disorders_2008.pdf. Accessed 25 Feb 2015

36. Ghoshal UC, Singh R, Chang FY, Hou X, Wong BC, Kachintorn U, Functional Dyspepsia Consensus Team of the Asian N, Motility A, the Asian Pacific Association of G (2011) Epidemiology of uninvestigated and functional dyspepsia in Asia: facts and fiction. J Neurogastroenterol Motil 17:235–244. doi:10.5056/jnm.2011.17.3.235

37. Clemens S, Begum N, Harper C, Whitty JA, Scuffham PA (2014) A comparison of EQ-5D-3L population norms in Queensland, Australia, estimated using utility value sets from Australia, the UK and USA. Qual Life Res 23:2375–2381. doi:10.1007/s11136-013-0676-4

38. Self-Reported Population Health: an international perspective based on EQ-5D (2014). 1 edn. Springer: Netherlands

39. Yu ST, Chang HY, Yao KP, Lin YH, Hung BS (2015) Validity of EQ-5D in general population of Taiwan: results of the 2009 National Health Interview and drug abuse survey of Taiwan. Qual Life Res 24:2541–2548. doi:10.1007/s11136-015-0978-7
Author/s:
Modi, A; Ebeling, PR; Lee, MS; Min, YK; Mithal, A; Yang, X; Baidya, S; Sen, S; Sajjan, S

Title:
Impact of gastrointestinal events on patient-reported outcomes in Asia-Pacific women with osteoporosis: baseline results of the MUSIC OS-AP study.

Date:
2017-12

Citation:
Modi, A., Ebeling, P. R., Lee, M. S., Min, Y. K., Mithal, A., Yang, X., Baidya, S., Sen, S. & Sajjan, S. (2017). Impact of gastrointestinal events on patient-reported outcomes in Asia-Pacific women with osteoporosis: baseline results of the MUSIC OS-AP study.. Arch Osteoporos, 12 (1), pp.65-. https://doi.org/10.1007/s11657-017-0350-3.

Persistent Link:
http://hdl.handle.net/11343/256581

File Description:
published version

License:
CC BY